venous use of the type IV phosphodiesterase inhibitor enoximone. ' We describe a case of tonic-clonic convulsions associated with intravenous administration of enoximone, a possible adverse effect that has hitherto not been reported.
A 66 year old white man was admitted with a large anteroseptal myocardial infarction due to occlusion of the left anterior descending coronary artery. He developed a ventricular septal defect within 48 hours of admission. An emergency closure of the defect was carried out with a Dacron patch in combination with double aortocoronary bypass grafting. Before the operation the patient was in severe heart failure, and at operation the infarction was seen to have affected the anterior two thirds of the interventricular septum.
After operation the patient required intra-aortic balloon counterpulsation in addition to infusions of adrenaline (0 04 Baillibre Tindall, 1985:590. Acute dystonia induced by midazolam and abolished by flumazenil Drs IWONA H STOLAREK and MICHAEL J FORD (Eastern General Hospital, Edinburgh EH6 7LN) write: Dystonic reactions are well recognised following the acute and chronic administration of phenothiazine and butyrophenone neuroleptic agents. Benzodiazepines have also been implicated in the development of tardive dyskinesias despite the fact that they arc used to treat such disorders.' We describe a patient who developed an acute dystonic reaction after intravenous midazolam which rapidly revcrscd after administration of the benzodiazepine antagonist flumazenil.
A previously fit 14 year old schoolboy taking no drugs underwent upper intestinal endoscopy in the investigation of dyspepsia. Sedation was achieved with midazolam 5 mg intravenously (0 1 mg/kg). He became acutely distressed and appeared to be resisting the procedure, which was then stopped. On examination he was conscious but mute and crying abnormally with intense akathisia and lingual dyskinesia. The acute dystonia was rapidly abolished after the administration of flumazenil 250 [tg intravenously.
Benzodiazepines facilitate the inhibitory effects of both y-aminobutryric acid at the presynaptic junction and glycine at the postsynaptic junction. ,-Aminobutyric acid and glycine are the two major inhibitory neurotransinitters and act as neurotransmitters at 50-75% of all synapses within the central nervous system. Their effects at receptor sites are competitively antagonised by flumazenil, an imidazobenzodiazepine.2
There are no published reports of acute dystonic reactions after intravenous midazolam, though several cases have been reported to the Committee on Safety of Medicines (personal communication Pharmacological provocation of hypertension in patients with phaeochromocytoma has been described for such psychotropic agents as tricyclic antidepressants.' To our knowledge there has been no such report implicating monoamine oxidase inhibitors. We report a phaeochromocytoma that presented as discrete episodes ofheadache, anxiety, and hypertension after a single dose of the monoamine oxidase inhibitor tranylcypromine had been given. A 37 year old white man was admitted to hospital for treatment of neurotic depression. Examination revealed marked agitation, depressed mood, and prominent suicidal thoughts of a recurrent obsessional nature. Physical examination was unremarkable apart from a blood pressure of 190/100 mm Hg in both arms, lying and standing. There were no neck or abdominal bruits. Examination of the optic fundi showed grade 1 hypertensive retinopathy. Although his blood pressure had been found to be mildly elevated at several previous medical examinations, the remainder of the medical history was unremarkable. The family history showed hypertension in both parents.
Initial treatment with mianserin 90 mg daily and chlordiazepoxide 25 mg three times a day supplemented by a short course of electroconvulsive therapy (six treatments in all) did not produce a satisfactory response. A monoamine oxidase inhibitor was therefore added to the regimen, and after a single dose of Parstelin (10 mg tranylcypromine and 1 mg trifluoperazine) he had three discrete episodes of acute anxiety, flushing, headache, and hypertension. The of a smooth round suprarenal mass 4 cm in diameter, which was removed at operation. Although cystic in nature, the tumour was seen on histological examination to be typical of phaeochromocytoma of benign type. Postoperatively the patient's blood pressure returned to normal, although his mental state remained largely unchanged. The actions of sympathomimetic amines are potentiated by monoamine oxidase inhibitors. The effect is greater with indirectly acting amines (tyramine, amphetamine) as catecholamines when given are largely inactivated by catechol-0-methyltransferase and by neuronal uptake.2 As monoamine oxidase constantly deaminates intracellular norepinephrine in presynaptic adrenergic neurons, however, provocation of hypertension in patients hypersecreting norepinephrine should be expected. Spontaneous hypertensive episodes produced by monoamine oxidase inhibitors have been described,' and it seems possible that, unless hypertension is a rare idiosyncratic reaction to monoamine oxidase inhibitors, these patients had an undiagnosed phaeochromocytoma. 614 BMJ VOLUME 300 3 MARCH 1990
